by Danny Sullivan – Longevity.Technology –
Longevity biotech Turn Biotechnologies today announced it has signed an exclusive global licensing agreement with Korean pharma giant HanAll Biopharma. The collaboration aims to develop multiple epigenetic reprogramming treatments for age-related eye and ear conditions, with the deal for the first product said to have a potential value of more than $300 million.
The agreement marks a significant expansion in the relationship between the two companies, building on HanAll’s 2022 investment in Turn Bio, which specializes in the development of treatments designed to repair tissue at a cellular level – restoring the youthful function of cells while maintaining their identity.
